ENT monitoring following radioactive iodine (RAI) therapy in patients treated for papillary thyroid carcinoma

Amal Chakroun; Mehdi Ferjani; Nour Kraiem; Nawres Bouaziz; Rachida Bouatay; Amel Korbi; Nawres Kolsi; Kamel Harrathi; Jamel Koubaa

doi:10.1530/endoabs.110.EP592

EP592

Prev Next

Section Contents Cite

Endocrine Abstracts (2025) 110 EP592 | DOI: 10.1530/endoabs.110.EP592

ECEESPE2025 ePoster Presentations Endocrine Related Cancer (100 abstracts)

ENT monitoring following radioactive iodine (RAI) therapy in patients treated for papillary thyroid carcinoma

Amal Chakroun ¹ , Mehdi Ferjani ² , Nour Kraiem ¹ , Nawres Bouaziz ¹ , Rachida Bouatay ¹ , Amel Korbi ¹ , Nawres Kolsi ¹ , Kamel Harrathi ¹ & Jamel Koubaa ¹

Author affiliations

¹Fattouma Bourguiba Hospital, ENT Departement, Monastir, Tunisia; ²Fattouma Bourguiba Hospital, Monastir, Tunisia

JOINT3563

Introduction: Radioactive iodine (RAI) therapy is an adjuvant treatment to reduce the risk of recurrence of papillary thyroid cancer (PTC).

Aim: To investigate the modalities and duration of follow up after RAI treatment.

Materials and Methods: Retrospective study of 22 patients with papillary thyroid carcinoma, treated with RAI and followed between the years 2020 and 2023.

Results: The mean age of patients was 43 years, with a female predominance (sex ratio = 0.19). The main symptom was a thyroid nodule in 19 cases, cervical adenopathy in 2 cases, and dysphagia in 1 case.Treatment consisted of Total thyroidectomy with central lymph node dissection in all patients, divided into total thyroidectomy in 10 patients and totalization after a first loboisthmectomy in 12 patients with lymph node dissection in 2 patients. The diagnosis was based on anatomopathological examination, which revealed papillary carcinoma in all patients. Treatment with RAI was carried out in 100% of cases, with a mean TG - OFF of 3.54 and mean Anti TG of 23.96. A whole-body scan was performed three days after high-dose iodine administration showing thyroid residues with no suspicious focus on the rest of the body in all patients. Biological follow up, carried out 4 months after the treatment, with an average TG of 0.1 and average anti TG of 0.2. During follow-up, every 3 to 6 months for the first 2 years, then at one year, none of the patients had a clinical, biological or radiological recurrence.

Conclusion: Surveillance in post RAI therapy in papillary thyroid cancer is crucial for early detection of recurrence and ensuring optimal patient management. Monitoring modalities, including serum thyroglobulin, cervical ultrasound, and, when necessary, functional imaging, are essential for assessing treatment response and guiding therapeutic strategies.